GoodRx Releases List of 30 Heart Medications Under $30
The cheapest medication on the list is hydrochlorothiazide at $4.55.
heart pills © bmarya83 - stock.adobe.com
The prescription cost-saving service GoodRx released today a list of 30 of the most common heart drugs that will be available to customers for under $30. The coupon codes will work at more than 70,000 pharmacies nationwide.
Cardiovascular disease currently affects almost half of Americans.
Some of the drugs available at the new rates are lisinopril, an ACE inhibitor, for $9.29; carvedilol, a beta blocker, for $10.68; and atorvastatin, a statin, for $10.10.
GoodRx has directly contributed to the prevention of at least 140,000 emergency room visits, according to their recent report, The GoodRx Effect.
“Improving access to affordable medications is the most important thing we can do to improve Americans’ heart health. The second most important is ensuring access to helpful, accurate information,” said Karla Robinson, MD, Medical Editor at GoodRx in a press release.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
